Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Lachlan, McIntosh"'
Autor:
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S. Hofman
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background PSMA PET/CT is a predictive and prognostic biomarker for determining response to [177Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be generalizable to n
Externí odkaz:
https://doaj.org/article/b04bf9cbe61641e8b0c83eb5935c6d9f
Autor:
Lachlan McIntosh, Price Jackson, Brittany Emmerson, James P. Buteau, Ramin Alipour, Grace Kong, Michael S. Hofman
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-10 (2024)
Abstract Background Terbium-161 (161Tb)-based radionuclide therapy poses an alternative to current Lutetium-177 (177Lu) approaches with the additional benefit of secondary Auger and conversion electron emissions capable of delivering high doses of lo
Externí odkaz:
https://doaj.org/article/4af472ac353143a988c71298c7ef360f
Autor:
Mathieu Gaudreault, David Chang, Nicholas Hardcastle, Lachlan McIntosh, Price Jackson, Tomas Kron, Cristian Udovicich, Michael S. Hofman, Shankar Siva
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 40, Iss , Pp 100608- (2023)
Background: Biology-guided radiotherapy (BgRT) is a novel treatment where the detection of positron emission originating from a volume called the biological tracking zone (BTZ) initiates dose delivery. Prostate-specific membrane antigen (PSMA) positr
Externí odkaz:
https://doaj.org/article/b2fb777b839e4bad9996fc3bc7b73305
Autor:
Lachlan McIntosh, Price Jackson, Nicholas Hardcastle, Mathias Bressel, Tomas Kron, Jason W. Callahan, Daniel Steinfort, Nicholas Bucknell, Michael S. Hofman, Shankar Siva
Publikováno v:
EJNMMI Physics, Vol 8, Iss 1, Pp 1-8 (2021)
Abstract Purpose Functional lung mapping from Ga68-ventilation/perfusion (V/Q) PET/CT, which has been shown to correlate with pulmonary function tests (PFTs), may be beneficial in a number of clinical applications where sparing regions of high lung f
Externí odkaz:
https://doaj.org/article/bba88791498e445594fa82b6c7ced9d6
Autor:
Ismael A. Vergara, Christopher P. Mintoff, Shahneen Sandhu, Lachlan McIntosh, Richard J. Young, Stephen Q. Wong, Andrew Colebatch, Daniel L. Cameron, Julia Lai Kwon, Rory Wolfe, Angela Peng, Jason Ellul, Xuelin Dou, Clare Fedele, Samantha Boyle, Gisela Mir Arnau, Jeanette Raleigh, Athena Hatzimihalis, Pacman Szeto, Jennifer Mooi, Daniel S. Widmer, Phil F. Cheng, Valerie Amann, Reinhard Dummer, Nicholas Hayward, James Wilmott, Richard A. Scolyer, Raymond J. Cho, David Bowtell, Heather Thorne, Kathryn Alsop, Stephen Cordner, Noel Woodford, Jodie Leditschke, Patricia O’Brien, Sarah-Jane Dawson, Grant A. McArthur, Graham J. Mann, Mitchell P. Levesque, Anthony T. Papenfuss, Mark Shackleton
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
The genetic changes that occur in late stage metastatic melanoma are not well delineated. Here, the authors use rapid autopsy samples from metastatic melanoma patients and show that the late stage in the disease is characterised by whole genome doubl
Externí odkaz:
https://doaj.org/article/4c17fb9d0e02463397deea2b50e28d35
Autor:
Mark Shackleton, Kieran F. Harvey, Anthony T. Papenfuss, Grant A. McArthur, Nicholas Hayward, Georgina V. Long, Helen Rizos, Evangeline Shaw, Katrina A. Mitchell, Lachlan McIntosh, Andrew Colebatch, Christopher Mintoff, Lie Yang, Pacman Szeto, Youfang Zhang, Ismael A. Vergara, Jian Zhong Tang, Xiaomeng Zhang
Expression of YAP, pYAP or TAZ proteins in 10 melanoma cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41735b01362f65a6324d78ef50ebee5e
https://doi.org/10.1158/1541-7786.22512409.v1
https://doi.org/10.1158/1541-7786.22512409.v1
Autor:
Mark Shackleton, Kieran F. Harvey, Anthony T. Papenfuss, Grant A. McArthur, Nicholas Hayward, Georgina V. Long, Helen Rizos, Evangeline Shaw, Katrina A. Mitchell, Lachlan McIntosh, Andrew Colebatch, Christopher Mintoff, Lie Yang, Pacman Szeto, Youfang Zhang, Ismael A. Vergara, Jian Zhong Tang, Xiaomeng Zhang
Melanoma is usually driven by mutations in BRAF or NRAS, which trigger hyperactivation of MAPK signaling. However, MAPK-targeted therapies are not sustainably effective in most patients. Accordingly, characterizing mechanisms that co-operatively driv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12cf2083a63aa0a263c73d0846a6dc6b
https://doi.org/10.1158/1541-7786.c.6540232.v1
https://doi.org/10.1158/1541-7786.c.6540232.v1
Autor:
Mark Shackleton, Kieran F. Harvey, Anthony T. Papenfuss, Grant A. McArthur, Nicholas Hayward, Georgina V. Long, Helen Rizos, Evangeline Shaw, Katrina A. Mitchell, Lachlan McIntosh, Andrew Colebatch, Christopher Mintoff, Lie Yang, Pacman Szeto, Youfang Zhang, Ismael A. Vergara, Jian Zhong Tang, Xiaomeng Zhang
Supplemental Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17cd8174f2de9cbd20a4adbc8b1b8fc0
https://doi.org/10.1158/1541-7786.22512394.v1
https://doi.org/10.1158/1541-7786.22512394.v1
Autor:
Borjana Bogdanovic, Esteban Lucas Solari, Alberto Villagran Asiares, Lachlan McIntosh, Sandra van Marwick, Sylvia Schachoff, Stephan G. Nekolla
Publikováno v:
Seminars in Nuclear Medicine. 52:340-355
When this article was written, it coincided with the 11th anniversary of the installation of our PET/MR device in Munich. In fact, this was the first fully integrated device to be in clinical use. During this time, we have observed many interesting b
Autor:
James Patrick Buteau, Louise Kathleen Kostos, Ramin Alipour, Price Jackson, Lachlan McIntosh, Brittany Emmerson, Mohammad B Haskali, Theresa Yeung, Sophia Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Nicole Ng, Maria Docanto, Patricia Bukczynska, Benjamin Blyth, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS281-TPS281
TPS281 Background: [177Lu]Lu-PSMA is an effective class of therapy for men with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response is partially explained by the presence of